| 9.8 0.05 (0.51%) | 04-22 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 16.43 | 1-year : | 19.73 |
| Resists | First : | 14.06 | Second : | 16.89 |
| Pivot price | 11.09  |
|||
| Supports | First : | 9.48 | Second : | 7.89 |
| MAs | MA(5) : | 10.34 |
MA(20) : | 11.79 |
| MA(100) : | 10.75  |
MA(250) : | 9.46 |
|
| MACD | MACD : | -1.1 |
Signal : | -0.9 |
| %K %D | K(14,3) : | 5.5 |
D(3) : | 4.9 |
| RSI | RSI(14): 28.2 |
|||
| 52-week | High : | 16.89 | Low : | 4.26 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ATXS ] has closed above bottom band by 7.2%. Bollinger Bands are 16.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 10.01 - 10.08 | 10.08 - 10.13 |
| Low: | 9.4 - 9.47 | 9.47 - 9.53 |
| Close: | 9.69 - 9.8 | 9.8 - 9.9 |
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
Wed, 17 Apr 2024
Astria Therapeutics (NASDAQ:ATXS) Stock Price Down 2.4% - MarketBeat
Tue, 16 Apr 2024
Astria Therapeutics (NASDAQ:ATXS) Trading 2.9% Higher - MarketBeat
Tue, 09 Apr 2024
Astria Therapeutics Expands Board, Appoints New Director - TipRanks.com - TipRanks
Wed, 03 Apr 2024
Chief Medical Officer Christopher Morabito Sells 10,000 Shares of Astria Therapeutics Inc (ATXS) - Yahoo Finance
Wed, 27 Mar 2024
Astria Therapeutics, Inc.'s (NASDAQ:ATXS) institutional investors lost 19% last week but have benefitted from longer-term gains - Simply Wall St
Mon, 25 Mar 2024
Astria Therapeutics (ATXS) Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 ... - StreetInsider.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 55 (M) |
| Shares Float | 36 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 88 (%) |
| Shares Short | 5,060 (K) |
| Shares Short P.Month | 1,700 (K) |
| EPS | -2.43 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.59 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -17.5 % |
| Return on Equity (ttm) | -31.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -68 (M) |
| Levered Free Cash Flow | -37 (M) |
| PE Ratio | -4.05 |
| PEG Ratio | 0 |
| Price to Book value | 2.72 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.87 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|